SK8312002A3 - Novel forms of pravastatin sodium - Google Patents

Novel forms of pravastatin sodium Download PDF

Info

Publication number
SK8312002A3
SK8312002A3 SK831-2002A SK8312002A SK8312002A3 SK 8312002 A3 SK8312002 A3 SK 8312002A3 SK 8312002 A SK8312002 A SK 8312002A SK 8312002 A3 SK8312002 A3 SK 8312002A3
Authority
SK
Slovakia
Prior art keywords
pravastatin sodium
pravastatin
solution
crystalline
solvent
Prior art date
Application number
SK831-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Vilmos Keri
Csaba Szabo
Edit Nagyne Arvai
Judith Aronhime
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26866349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK8312002(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of SK8312002A3 publication Critical patent/SK8312002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK831-2002A 1999-12-14 2000-12-14 Novel forms of pravastatin sodium SK8312002A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17068599P 1999-12-14 1999-12-14
US19064900P 2000-03-20 2000-03-20
PCT/US2000/033867 WO2001043723A1 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium

Publications (1)

Publication Number Publication Date
SK8312002A3 true SK8312002A3 (en) 2003-05-02

Family

ID=26866349

Family Applications (1)

Application Number Title Priority Date Filing Date
SK831-2002A SK8312002A3 (en) 1999-12-14 2000-12-14 Novel forms of pravastatin sodium

Country Status (15)

Country Link
US (3) US7001919B2 (xx)
EP (1) EP1242051A4 (xx)
JP (2) JP2003516959A (xx)
KR (1) KR20020062340A (xx)
CN (1) CN1434702A (xx)
AU (1) AU779306B2 (xx)
CA (1) CA2394200C (xx)
CZ (1) CZ20021998A3 (xx)
HK (1) HK1049441A1 (xx)
HU (1) HUP0204005A3 (xx)
IL (1) IL150187A0 (xx)
PL (1) PL364929A1 (xx)
SK (1) SK8312002A3 (xx)
WO (1) WO2001043723A1 (xx)
YU (1) YU45202A (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204005A3 (en) * 1999-12-14 2003-05-28 Teva Gyogyszergyar Zartkoeruee Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
ES2292721T3 (es) * 2001-03-27 2008-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivado de isoxazol cristalino y preparacion medica del mismo.
EP1737449A1 (en) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Pharmaceutical composition
EP1786414A4 (en) 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
EP1833780A1 (en) * 2005-02-09 2007-09-19 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Methods of making pravastatin sodium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
WO2012085191A1 (en) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Crystalline form of pravastatine and process for the preparation thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949062B (zh) * 2016-06-24 2017-06-13 广东蓝宝制药有限公司 一种规模化制备普伐他汀钠d型晶体的工艺
CN111018714B (zh) * 2019-12-27 2020-09-04 广东蓝宝制药有限公司 一种获得高纯a晶型普伐他汀钠的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
EP0215665B1 (en) 1985-09-13 1991-11-21 Sankyo Company Limited Hydroxy-ml-236b derivatives, their preparation and use
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
NZ250609A (en) 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6165757A (en) 1997-02-20 2000-12-26 Dsm N.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
EP1015600A1 (en) 1997-08-22 2000-07-05 Dsm N.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
PL350317A1 (en) 1999-02-03 2002-12-02 Inst Drug Res Ltd Microbial process for preparing pravastatin
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
KR20030026920A (ko) 1999-11-30 2003-04-03 비오갈 기오기스제르갸르 알티. 발효 브로스로부터 스타틴 화합물의 수집 방법
HUP0204005A3 (en) * 1999-12-14 2003-05-28 Teva Gyogyszergyar Zartkoeruee Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
AU2002211462A1 (en) 2000-10-05 2002-04-22 Teva Gyogyszergyar Reszvenytarsasag Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
DE10209305A1 (de) 2001-04-30 2002-10-31 Basf Ag Thermische Spaltung von Allophanaten

Also Published As

Publication number Publication date
AU779306B2 (en) 2005-01-13
US20070197633A1 (en) 2007-08-23
CA2394200C (en) 2006-10-03
JP2005120105A (ja) 2005-05-12
IL150187A0 (en) 2002-12-01
HK1049441A1 (zh) 2003-05-16
HUP0204005A3 (en) 2003-05-28
PL364929A1 (en) 2004-12-27
CN1434702A (zh) 2003-08-06
KR20020062340A (ko) 2002-07-25
US20050288370A1 (en) 2005-12-29
JP2003516959A (ja) 2003-05-20
US20010041809A1 (en) 2001-11-15
US7262218B2 (en) 2007-08-28
CZ20021998A3 (cs) 2003-02-12
US7001919B2 (en) 2006-02-21
EP1242051A4 (en) 2004-05-12
WO2001043723A1 (en) 2001-06-21
HUP0204005A2 (hu) 2003-03-28
EP1242051A1 (en) 2002-09-25
CA2394200A1 (en) 2001-06-21
AU2098701A (en) 2001-06-25
YU45202A (sh) 2005-11-28

Similar Documents

Publication Publication Date Title
US7262218B2 (en) Forms of pravastatin sodium
JP6359971B2 (ja) イバブラジン塩酸塩の形態ｉｖ
EP0907639B1 (en) Polymorphic compounds
US20050192236A1 (en) Crystaline clindamycin free base
KR20220017932A (ko) 타파미디스 및 그 염의 고상형
NO312513B1 (no) Mesylat-trihydrat av 5-(2-(4-(1,2-benzoisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on(=ziperasidone), og farmasöytisk blanding for behandling avpsykotisk forstyrrelse
JP2006249105A (ja) ゾルピデムヘミタートレイト
EP3938363A1 (en) Solid state forms of ripretinib
SK8872002A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
EA028769B1 (ru) Фармацевтические композиции, содержащие рифаксимин и аминокислоты, способ их получения и их применение
WO2023064519A1 (en) Solid state forms of elacestrant and processes for preparation thereof
AU2011334928A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
JP2023509242A (ja) 新規なエンパグリフロジンの共結晶
EP2601175A1 (en) A novel crystalline compound comprising saxagliptin and phosphoric acid
KR20090045419A (ko) 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
CN108239055B (zh) 一种thr1442 l-天冬氨酸共晶、其制备方法及药物组合物
WO2023091534A1 (en) Solid state form of tafamidis
WO2021119223A1 (en) Solid state form of lemborexant
EP1523978A2 (en) Crystalline forms of pravastatin sodium
CA2551203A1 (en) Novel forms of pravastatin sodium
WO2020154581A1 (en) Solid state forms of fedovapagon-salicyclic acid co-crystal
WO2023287938A1 (en) Solid state forms of amcenestrant
KR20230087557A (ko) 로레시비빈트의 고상형
WO2024121805A1 (en) Solid state forms of zipalertinib and process for preparation thereof
JPH08231510A (ja) 新規光学活性アミノピリジン誘導体結晶、その製法および用途